Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXEL Exelixis	$36.36 -1.8%	$35.48	$20.14 ▼ $40.02	$10.18B	0.57	2.07 million shs	1.93 million shs
GILD Gilead Sciences	$110.23 -1.8%	$102.63	$62.07 ▼ $119.96	$139.80B	0.21	6.69 million shs	10.25 million shs
MDCO Medicines	$84.90	$84.90	$17.81 ▼ $84.98	$6.77B	1.1	9.55 million shs	N/A
NVS Novartis	$112.23 +0.0%	$105.92	$92.35 ▼ $120.92	$229.38B	0.53	1.44 million shs	3.96 million shs
ON Onsemi	$43.42 -1.4%	$50.80	$41.59 ▼ $80.08	$18.30B	1.59	6.79 million shs	5.28 million shs
PFE Pfizer	$26.31 +1.0%	$26.21	$24.48 ▼ $31.54	$149.09B	0.61	35.80 million shs	32.95 million shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXEL Exelixis	-1.78%	-1.54%	+3.89%	+8.02%	+56.93%
GILD Gilead Sciences	-1.81%	-3.67%	+5.91%	+21.55%	+50.46%
MDCO Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
NVS Novartis	-0.01%	+0.67%	+6.45%	+15.90%	+17.00%
ON Onsemi	-1.43%	+1.31%	-16.23%	-33.13%	-41.18%
PFE Pfizer	+0.92%	+1.19%	+3.18%	+1.61%	-5.17%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EXEL Exelixis	4.6025 of 5 stars	2.3	4.0	0.0	4.3	2.8	2.5	3.1
GILD Gilead Sciences	4.4242 of 5 stars	2.4	3.0	1.7	4.1	2.9	2.5	1.9
MDCO Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVS Novartis	2.3108 of 5 stars	1.9	3.0	2.5	0.0	2.8	0.0	1.9
ON Onsemi	4.7962 of 5 stars	4.3	2.0	0.0	3.2	2.9	1.7	3.1
PFE Pfizer	4.983 of 5 stars	3.3	3.0	4.2	4.2	2.8	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXEL Exelixis	2.50	Moderate Buy	$37.59	3.38% Upside
GILD Gilead Sciences	2.72	Moderate Buy	$104.52	-5.18% Downside
MDCO Medicines	0.00	N/A	N/A	N/A
NVS Novartis	1.80	Reduce	$123.38	9.93% Upside
ON Onsemi	2.52	Moderate Buy	$66.85	53.95% Upside
PFE Pfizer	2.59	Moderate Buy	$31.92	21.35% Upside

Current Analyst Ratings Breakdown

Latest EXEL, GILD, NVS, ON, PFE, and MDCO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	EXEL Exelixis	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$38.00 ➝ $40.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/11/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$123.00 ➝ $130.00
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/7/2025	ON Onsemi	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$60.00
3/5/2025	GILD Gilead Sciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$116.00 ➝ $126.00
3/5/2025	GILD Gilead Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $140.00
3/4/2025	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$115.00 ➝ $132.00
3/3/2025	ON Onsemi	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
2/27/2025	ON Onsemi	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$49.00 ➝ $49.00

(Data available from 3/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXEL Exelixis	$2.17B	4.69	$2.00 per share	18.22	$8.02 per share	4.53
GILD Gilead Sciences	$28.75B	4.77	$8.71 per share	12.66	$15.44 per share	7.14
MDCO Medicines	$6.14M	1,102.36	N/A	N/A	($0.30) per share	-283.00
NVS Novartis	$51.72B	4.44	$11.19 per share	10.03	$21.59 per share	5.20
ON Onsemi	$7.08B	2.58	$4.32 per share	10.06	$20.92 per share	2.08
PFE Pfizer	$63.63B	2.34	$4.12 per share	6.38	$15.81 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXEL Exelixis	$521.27M	$1.77	20.54	14.26	1.13	24.04%	23.52%	17.95%	4/3/2025 (Confirmed)
GILD Gilead Sciences	$480M	$0.37	297.92	13.59	0.71	1.67%	31.63%	10.38%	4/24/2025 (Estimated)
MDCO Medicines	-$123.16M	-$2.91	N/A	N/A	N/A	N/A	N/A	-25.70%	N/A
NVS Novartis	$11.94B	$5.88	19.09	12.74	1.70	23.56%	37.24%	15.85%	4/22/2025 (Estimated)
ON Onsemi	$1.57B	$3.63	11.96	11.80	16.74	22.21%	20.10%	12.36%	4/28/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	18.66	8.68	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)

Latest EXEL, GILD, NVS, ON, PFE, and MDCO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/11/2025	Q4 2024	EXEL Exelixis	$0.51	$0.48	-$0.03	$0.48	$563.23 million	N/A
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A
2/10/2025	Q4 2024	ON Onsemi	$0.98	$0.95	-$0.03	$0.88	$1.76 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/31/2025	Q4 2024	NVS Novartis	$1.80	$1.98	+$0.18	$1.41	$12.86 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.87%	+2.74%	854.05%	N/A
MDCO Medicines	N/A	N/A	N/A	N/A	N/A
NVS Novartis	$2.51	2.24%	+5.34%	42.69%	N/A
ON Onsemi	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.54%	+2.50%	121.99%	16 Years

Latest EXEL, GILD, NVS, ON, PFE, and MDCO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025
2/20/2025	NVS Novartis		$3.8695		3/12/2025	3/12/2025	3/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXEL Exelixis	N/A	3.63	3.58
GILD Gilead Sciences	1.24	1.50	1.20
MDCO Medicines	21.45	0.77	0.77
NVS Novartis	0.48	1.04	0.84
ON Onsemi	0.38	5.06	3.38
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXEL Exelixis	85.27%
GILD Gilead Sciences	83.67%
MDCO Medicines	N/A
NVS Novartis	13.12%
ON Onsemi	97.70%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
EXEL Exelixis	2.85%
GILD Gilead Sciences	0.29%
MDCO Medicines	8.41%
NVS Novartis	0.01%
ON Onsemi	0.31%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXEL Exelixis	1,147	279.88 million	271.90 million	Optionable
GILD Gilead Sciences	18,000	1.25 billion	1.24 billion	Optionable
MDCO Medicines	62	79.72 million	N/A	Optionable
NVS Novartis	75,883	2.04 billion	2.04 billion	Optionable
ON Onsemi	26,490	421.42 million	420.12 million	Optionable
PFE Pfizer	88,000	5.67 billion	5.66 billion	Optionable

EXEL, GILD, NVS, ON, PFE, and MDCO Headlines

Recent News About These Companies

Pfizer offers for sale entire residual shareholding in Haleon

March 18 at 9:34 PM | markets.businessinsider.com

5PFE : 4 Analysts Assess Pfizer: What You Need To Know

March 18 at 9:34 PM | benzinga.com

Analyst Says Pfizer (PFE) Stock Will ‘Move Too Fast to Catch’

March 18 at 9:34 PM | msn.com

JPMorgan remains cautious on Pfizer’s danuglipron with Phase 3 decision upcoming

March 18 at 4:33 PM | markets.businessinsider.com

Pfizer plans to sell final stake in Sensodyne producer Haleon - Bloomberg

March 18 at 2:50 PM | investing.com

Pfizer (NYSE:PFE) Trading 0.8% Higher - Should You Buy?

March 18 at 1:20 PM | marketbeat.com

Haleon PLC to Buy Back Shares in Agreement with Pfizer

March 18 at 12:58 PM | tipranks.com

Pfizer to dispose of entire Haleon stake

March 18 at 12:54 PM | reuters.com

Russia’s Axelpharm continues disputes with Pfizer over generic axitinib

March 18 at 11:33 AM | thepharmaletter.com

Pfizer Inc. (PFE): One of the Most Profitable Value Stocks to Buy Now

March 18 at 11:33 AM | msn.com

Pfizer (NYSE:PFE) Earns "Buy" Rating from Guggenheim

March 18 at 10:37 AM | marketbeat.com

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

March 18 at 10:06 AM | zacks.com

Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts

March 18 at 10:00 AM | businesswire.com

Enhancing Capital LLC Invests $1.10 Million in Pfizer Inc. (NYSE:PFE)

March 18 at 7:15 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Xponance Inc.

March 18 at 7:14 AM | marketbeat.com

Generali Asset Management SPA SGR Buys Shares of 434,919 Pfizer Inc. (NYSE:PFE)

March 18 at 7:04 AM | marketbeat.com

Advisors Asset Management Inc. Buys 59,283 Shares of Pfizer Inc. (NYSE:PFE)

March 18 at 6:46 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Mystic Asset Management Inc.

March 18 at 6:20 AM | marketbeat.com

RD Lewis Holdings Inc. Invests $617,000 in Pfizer Inc. (NYSE:PFE)

March 18 at 6:12 AM | marketbeat.com

Argent Advisors Inc. Has $2.31 Million Stake in Pfizer Inc. (NYSE:PFE)

March 18 at 5:53 AM | marketbeat.com

Tocqueville Asset Management L.P. Sells 166,090 Shares of Pfizer Inc. (NYSE:PFE)

March 18 at 5:43 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings
Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Archer Aviation Stock Skids: Mistaking Progress for Bad News?
By Chris Markoch | February 24, 2025
View Archer Aviation Stock Skids: Mistaking Progress for Bad News?
3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
By Gabriel Osorio-Mazilli | February 21, 2025
View 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom

EXEL, GILD, NVS, ON, PFE, and MDCO Company Descriptions

Exelixis NASDAQ:EXEL

$36.36 -0.66 (-1.78%)

Closing price 03/18/2025 04:00 PM Eastern

Extended Trading

$36.54 +0.18 (+0.51%)

As of 03/18/2025 06:40 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Gilead Sciences NASDAQ:GILD

$110.23 -2.03 (-1.81%)

Closing price 03/18/2025 04:00 PM Eastern

Extended Trading

$107.19 -3.04 (-2.76%)

As of 03/18/2025 07:59 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Medicines NASDAQ:MDCO

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Novartis NYSE:NVS

$112.23 +0.01 (+0.01%)

Closing price 03/18/2025 03:59 PM Eastern

Extended Trading

$112.23 +0.00 (+0.00%)

As of 03/18/2025 07:50 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Onsemi NASDAQ:ON

$43.42 -0.63 (-1.43%)

Closing price 03/18/2025 04:00 PM Eastern

Extended Trading

$43.32 -0.11 (-0.24%)

As of 03/18/2025 07:58 PM Eastern

onsemi is engaged in disruptive innovations and also a supplier of power and analog semiconductors. The firm offers vehicle electrification and safety, sustainable energy grids, industrial automation, and 5G and cloud infrastructure, with a focus on automotive and industrial end-markets. It operates through the following segments: Power Solutions Group, Advanced Solutions Group, and Intelligent Sensing Group. The Power Solutions Group segment offers discrete, module, and semiconductor products that perform multiple application functions, including power switching, power conversion, signal conditioning, circuit protection, signal amplification, and voltage reference functions. The Advanced Solutions Group segment is involved in the designing and developing of analog, mixed-signal, advanced logic, ASSPs and ASICs, Wi-Fi and power solutions for a broad base of end-users in the automotive, consumer, computing, industrial, communications, medical and aerospace/defense markets. The Intelligent Sensing Group segment is focused on the designing and developing of CMOS and CCD image sensors, as well as proximity sensors, image signal processors, single photon detectors, inclu

Pfizer NYSE:PFE

$26.31 +0.26 (+0.99%)

Closing price 03/18/2025 03:59 PM Eastern

Extended Trading

$26.31 +0.00 (+0.01%)

As of 03/18/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXEL, GILD, NVS, ON, PFE, and MDCO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXEL, GILD, NVS, ON, PFE, and MDCO Earnings

Compare Dividends

Latest EXEL, GILD, NVS, ON, PFE, and MDCO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXEL, GILD, NVS, ON, PFE, and MDCO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EXEL, GILD, NVS, ON, PFE, and MDCO Company Descriptions

Exelixis NASDAQ:EXEL

Gilead Sciences NASDAQ:GILD

Medicines NASDAQ:MDCO

Novartis NYSE:NVS

Onsemi NASDAQ:ON

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools